ICO.V - iCo Therapeutics Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.04
0.00 (0.00%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.04
Open0.05
Bid0.04 x 0
Ask0.04 x 0
Day's Range0.04 - 0.05
52 Week Range0.04 - 0.07
Volume178,000
Avg. Volume397,748
Market Cap3.378M
Beta3.62
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Associated Press14 days ago

    Ico Therapeutics posts 3Q loss

    The Vancouver, British Columbia-based company said it had a loss of less than 1 cent on a per-share basis. In the final minutes of trading on Tuesday, the company's shares hit 3 cents. A year ago, they ...

  • What You Must Know About iCo Therapeutics Inc’s (TSXV:ICO) Risks
    Simply Wall St.3 months ago

    What You Must Know About iCo Therapeutics Inc’s (TSXV:ICO) Risks

    If you are a shareholder in iCo Therapeutics Inc’s (TSXV:ICO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Associated Press3 months ago

    Ico Therapeutics posts 2Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of less than 1 cent. In the final minutes of trading on Tuesday, the company's shares hit 4 cents. A year ago, they ...

  • Newsfile3 months ago

    iCo Therapeutics Announces Second Quarter 2017 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - August 29, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended June 30, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS")."During the quarter, we reported the results of our preclinical, 14-day, GLP toxicology study with our novel Oral Amphotericin B (Oral Amp B) candidate. We were pleased ...

  • Newsfile4 months ago

    iCo Therapeutics Inc. Approves Advance Notice Policy

    Vancouver, British Columbia--(Newsfile Corp. - August 4, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") today announced that its board of directors has adopted an advance notice policy (the "Advance Notice Policy").The purpose of the Advance Notice Policy is to provide shareholders, directors and management of the Company with direction on the procedure for shareholder nomination of directors. The Advance Notice Policy is the framework by which the Company seeks to ...

  • Newsfile5 months ago

    iCo Therapeutics Announces Election of Directors

    Vancouver, British Columbia--(Newsfile Corp. - June 30, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the election of directors at the annual meeting of shareholders held on June 29, 2017. At the annual meeting of shareholders held on June 29, 2017, Andrew Rae, Susan Koppy, Wiiliam Jarosz and Michael Liggett were elected directors of the Company and will hold office until the next annual general meeting ...

  • Newsfile6 months ago

    iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset

    Vancouver, British Columbia--(Newsfile Corp. - June 15, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported it will hold a pre IND meeting with the Division of Transplantation and Ophthalmology, US Food and Drug Administration (FDA) on June 21st, 2017. Discussions will focus on a proprietary dual action glaucoma asset with a novel mechanism of action that reduces intraocular pressure (IOP). The target is validated by literature and a ...

  • Newsfile6 months ago

    iCo Therapeutics Announces Positive Oral Amphotericin Study

    Vancouver, British Columbia--(Newsfile Corp. - June 12, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported the successful conclusion of pre-clinical studies involving its lead oral Amphotericin B candidate, including compelling safety data from its pivotal 14 day GLP (Good Laboratory Practices compliant) toxicology study.Data from its IND enabling 14 day GLP study conducted in Toronto, Ontario facilities revealed that oral administration of Amphotericin B at a dose levels of ...

  • Associated Press7 months ago

    Ico Therapeutics posts 1Q loss

    The Vancouver, British Columbia-based company said it had a loss of less than 1 cent on a per-share basis. In the final minutes of trading on Wednesday, the company's shares hit 3 cents. A year ago, they ...

  • Newsfile7 months ago

    iCo Therapeutics Announces First Quarter 2017 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - May 24, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended March 31, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS")."During the first quarter, we substantially completed our preclinical, 14-day, GLP toxicology study with our novel Oral Amphotericin B (Oral Amp B) candidate. We currently expect to receive ...